US IPO Weekly Recap: Artisan Partners delivers best IPO pop from a US asset ... NASDAQ The company's lead drug candidate is expected to begin Phase 3 trials in 2013 for the prevention of CMV (cytomegalovirus), an infection found in certain stem cell transplant patients. It also has developed a preclinical compound for the treatment of HIV. |
